Published in
American Association for the Advancement of Science, Science Translational Medicine, 401(9), 2017
DOI: 10.1126/scitranslmed.aam7049
Links
Tools
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Journal article published in 2017 by
Delphine Merino 
,
James R. Whittle ,
François Vaillant ,
Antonin Serrano,
Jia-Nan Gong ,
Goknur Giner,
Ana Leticia Maragno,
Maïa Chanrion,
Emilie Schneider,
Bhupinder Pal,
Xiang Li,
Grant Dewson,
Julius Gräsel,
Kevin Liu,
Najoua Lalaoui
and other authors.
,
James R. Whittle ,
François Vaillant ,
Antonin Serrano,
Jia-Nan Gong ,
Goknur Giner,
Ana Leticia Maragno,
Maïa Chanrion,
Emilie Schneider,
Bhupinder Pal,
Xiang Li,
Grant Dewson,
Julius Gräsel,
Kevin Liu,
Najoua Lalaoui
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The MCL-1 inhibitor S63845 is effective in combination with conventional therapy for targeting triple-negative and HER2-amplified breast cancer.